Roche RHHBY introduced that it’s voluntarily withdrawing the indication of prior-platinum-treated metastatic urothelial carcinoma (mUC, bladder most cancers) for immuno-oncology drug, Tecentriq (atezolizumab), in america. www.nasdaq.com
Roche RHHBY introduced that it’s voluntarily withdrawing the indication of prior-platinum-treated metastatic urothelial carcinoma (mUC, bladder most cancers) for immuno-oncology drug, Tecentriq (atezolizumab), in america.
www.nasdaq.com